‘If we implement the manufacturing of this vaccine in our facilities, we will become one of the components of the distribution of this vaccine within Novavax,’ said Mabion's CEO. 

 

He also informed that it is too early to say which markets the Polish vaccine would reach. The Polish government has a contract with Novavax for 8 million doses, but within the European Union, so it is not known exactly where each vaccine will go.

 

‘Novavax vaccine, if approved for use in the European Union, could be available in Poland practically from the next day,’ said Mabion's CEO. 

 

Paweł Borys pointed out that all manufacturers were struggling with their production capacities, which resulted in problems with vaccine availability in the European Union as well. ‘We are confident that this investment increases the safety of the entire vaccination program,’ added the PFR President.